The different contributions of the industry in public-private partnerships in Rare Diseases Research continuum

IRDiRC is delighted to present the outcome of the collaboration between the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Rare Disease Moonshot and the IRDiRC Companies Constituent Committee: “The different contributions of the industry in Public-Private Partnerships in Rare Diseases Research continuum” report, which marks a pivotal moment in research advancement, innovation and treatment for RDs.

This new report highlights the unique value pharmaceutical and biotech companies bring to Public-Private Partnerships (PPPs).


Key takeaways:
Scientific & Regulatory Expertise
Companies provide cutting-edge infrastructure, data, technical know-how, and a deep understanding of regulatory pathways.

Operational Capacity
With a global footprint and strong project management skills, industry partners help scale innovations, manage risks, and drive efficient implementation.

Collaborative Leadership & Patient-Centric Approach
Industry actors know how to meaningfully engage patient organizations early in the R&D process, supporting co-creation of impactful solutions.

A Strategic Role in Rare Diseases
In a fragmented and resource-scarce field, industry involvement helps connect the dots, enrich efforts with real-world data, and accelerate impact.


Link to full report: https://lnkd.in/ej3Uccee